Baidu
map

AIM:泼尼松龙是治疗急性痛风的有效和安全的一线治疗选择

2016-02-26 MedSci MedSci原创

最近两项次双盲随机对照试验(RCT)表明,口服类固醇和非类固醇抗炎药对痛风的治疗有类似的镇痛效果,但试验样本量小,还有一些方法的局限性。该研究的目的是比较口服泼尼松龙 vs 消炎痛对急救部门(EDS)的急性痛风患者的有效性和安全性。该研究为一项多中心,双盲,随机等效性试验。患者被随机分配:接受或消炎痛或泼尼松龙(1:1的比例)。该研究在香港的4个EDs进行。共包括416例18岁及以上的患者。镇痛的

最近两项双盲随机对照试验(RCT)表明,口服类固醇和非类固醇抗炎药对痛风的治疗有类似的镇痛效果,但试验样本量小,还有一些方法的局限性。

该研究的目的是比较口服泼尼松龙 vs 消炎痛对急救部门(EDS)的急性痛风患者的有效性和安全性。

该研究为一项多中心、双盲、随机等效性试验。患者被随机分配:接受或消炎痛或泼尼松龙(1:1的比例)。该研究在香港的4个EDs进行。共包括416例18岁及以上的患者。

镇痛的有效性被定义为疼痛的变化(静止或活动)在100mm视觉模拟评分中大于13mm。结果是在急救前2小时以及1天到14天是测定的。

376名患者完成了这项研究。在ED(约10mm[休息]和20mm[活动])和从1天到14天(大约25mm[休息]和45mm[活动])时,消炎痛组和泼尼松龙组的患者都观察到平均疼痛评分减少的等效性和临床显著性。在研究过程中无重大不良事件发生。在ED阶段,消炎痛组的患者比泼尼松龙组的患者有更多的轻微不良事件(19% vs 6%,P<0.001)。在第1到14天中,各组患者中有37%有轻微的不良事件。

该研究的限制性为痛风的诊断通常是基于临床标准,而不是关节液的检查。

对于急性痛风的患者,口服强的松和消炎痛有相似的镇痛效果。泼尼松龙是用于治疗急性痛风的有效和安全的一线治疗选择。

原始出处:

Timothy Hudson Rainer,Chi Hung Cheng,Hein J.E.M. Janssens,et al.Oral Prednisolone in the Treatment of Acute Gout,Ann Intern Med,2016.2.23

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (15)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951427, encodeId=18f4195142e64, content=<a href='/topic/show?id=25305234439' target=_blank style='color:#2F92EE;'>#急性痛风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52344, encryptionId=25305234439, topicName=急性痛风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Nov 03 04:43:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772688, encodeId=e6931e7268874, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Thu Sep 08 12:43:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66124, encodeId=856966124e3, content=看看吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66125, encodeId=4f9b661257b, content=先学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553884, encodeId=5ad8155388416, content=<a href='/topic/show?id=adbe650e465' target=_blank style='color:#2F92EE;'>#泼尼松龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65074, encryptionId=adbe650e465, topicName=泼尼松龙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4914457810, createdName=xjy07, createdTime=Sun Feb 28 09:43:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66063, encodeId=be62660638f, content=不太懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat Feb 27 23:11:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66038, encodeId=23566603856, content=内分泌科常用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66039, encodeId=596c6603936, content=副作用挺大的, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66040, encodeId=85786604051, content=慎重用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66041, encodeId=828966041d2, content=双刃剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1951427, encodeId=18f4195142e64, content=<a href='/topic/show?id=25305234439' target=_blank style='color:#2F92EE;'>#急性痛风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52344, encryptionId=25305234439, topicName=急性痛风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Nov 03 04:43:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772688, encodeId=e6931e7268874, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Thu Sep 08 12:43:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66124, encodeId=856966124e3, content=看看吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66125, encodeId=4f9b661257b, content=先学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553884, encodeId=5ad8155388416, content=<a href='/topic/show?id=adbe650e465' target=_blank style='color:#2F92EE;'>#泼尼松龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65074, encryptionId=adbe650e465, topicName=泼尼松龙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4914457810, createdName=xjy07, createdTime=Sun Feb 28 09:43:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66063, encodeId=be62660638f, content=不太懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat Feb 27 23:11:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66038, encodeId=23566603856, content=内分泌科常用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66039, encodeId=596c6603936, content=副作用挺大的, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66040, encodeId=85786604051, content=慎重用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66041, encodeId=828966041d2, content=双刃剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1951427, encodeId=18f4195142e64, content=<a href='/topic/show?id=25305234439' target=_blank style='color:#2F92EE;'>#急性痛风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52344, encryptionId=25305234439, topicName=急性痛风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Nov 03 04:43:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772688, encodeId=e6931e7268874, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Thu Sep 08 12:43:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66124, encodeId=856966124e3, content=看看吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66125, encodeId=4f9b661257b, content=先学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553884, encodeId=5ad8155388416, content=<a href='/topic/show?id=adbe650e465' target=_blank style='color:#2F92EE;'>#泼尼松龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65074, encryptionId=adbe650e465, topicName=泼尼松龙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4914457810, createdName=xjy07, createdTime=Sun Feb 28 09:43:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66063, encodeId=be62660638f, content=不太懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat Feb 27 23:11:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66038, encodeId=23566603856, content=内分泌科常用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66039, encodeId=596c6603936, content=副作用挺大的, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66040, encodeId=85786604051, content=慎重用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66041, encodeId=828966041d2, content=双刃剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=)]
    2016-02-28 忠诚向上

    看看吧

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1951427, encodeId=18f4195142e64, content=<a href='/topic/show?id=25305234439' target=_blank style='color:#2F92EE;'>#急性痛风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52344, encryptionId=25305234439, topicName=急性痛风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Nov 03 04:43:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772688, encodeId=e6931e7268874, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Thu Sep 08 12:43:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66124, encodeId=856966124e3, content=看看吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66125, encodeId=4f9b661257b, content=先学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553884, encodeId=5ad8155388416, content=<a href='/topic/show?id=adbe650e465' target=_blank style='color:#2F92EE;'>#泼尼松龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65074, encryptionId=adbe650e465, topicName=泼尼松龙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4914457810, createdName=xjy07, createdTime=Sun Feb 28 09:43:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66063, encodeId=be62660638f, content=不太懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat Feb 27 23:11:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66038, encodeId=23566603856, content=内分泌科常用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66039, encodeId=596c6603936, content=副作用挺大的, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66040, encodeId=85786604051, content=慎重用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66041, encodeId=828966041d2, content=双刃剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=)]
    2016-02-28 忠诚向上

    先学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1951427, encodeId=18f4195142e64, content=<a href='/topic/show?id=25305234439' target=_blank style='color:#2F92EE;'>#急性痛风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52344, encryptionId=25305234439, topicName=急性痛风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Nov 03 04:43:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772688, encodeId=e6931e7268874, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Thu Sep 08 12:43:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66124, encodeId=856966124e3, content=看看吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66125, encodeId=4f9b661257b, content=先学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553884, encodeId=5ad8155388416, content=<a href='/topic/show?id=adbe650e465' target=_blank style='color:#2F92EE;'>#泼尼松龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65074, encryptionId=adbe650e465, topicName=泼尼松龙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4914457810, createdName=xjy07, createdTime=Sun Feb 28 09:43:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66063, encodeId=be62660638f, content=不太懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat Feb 27 23:11:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66038, encodeId=23566603856, content=内分泌科常用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66039, encodeId=596c6603936, content=副作用挺大的, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66040, encodeId=85786604051, content=慎重用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66041, encodeId=828966041d2, content=双刃剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1951427, encodeId=18f4195142e64, content=<a href='/topic/show?id=25305234439' target=_blank style='color:#2F92EE;'>#急性痛风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52344, encryptionId=25305234439, topicName=急性痛风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Nov 03 04:43:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772688, encodeId=e6931e7268874, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Thu Sep 08 12:43:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66124, encodeId=856966124e3, content=看看吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66125, encodeId=4f9b661257b, content=先学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553884, encodeId=5ad8155388416, content=<a href='/topic/show?id=adbe650e465' target=_blank style='color:#2F92EE;'>#泼尼松龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65074, encryptionId=adbe650e465, topicName=泼尼松龙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4914457810, createdName=xjy07, createdTime=Sun Feb 28 09:43:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66063, encodeId=be62660638f, content=不太懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat Feb 27 23:11:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66038, encodeId=23566603856, content=内分泌科常用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66039, encodeId=596c6603936, content=副作用挺大的, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66040, encodeId=85786604051, content=慎重用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66041, encodeId=828966041d2, content=双刃剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=)]
    2016-02-27 wei834766788

    不太懂

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1951427, encodeId=18f4195142e64, content=<a href='/topic/show?id=25305234439' target=_blank style='color:#2F92EE;'>#急性痛风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52344, encryptionId=25305234439, topicName=急性痛风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Nov 03 04:43:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772688, encodeId=e6931e7268874, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Thu Sep 08 12:43:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66124, encodeId=856966124e3, content=看看吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66125, encodeId=4f9b661257b, content=先学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553884, encodeId=5ad8155388416, content=<a href='/topic/show?id=adbe650e465' target=_blank style='color:#2F92EE;'>#泼尼松龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65074, encryptionId=adbe650e465, topicName=泼尼松龙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4914457810, createdName=xjy07, createdTime=Sun Feb 28 09:43:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66063, encodeId=be62660638f, content=不太懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat Feb 27 23:11:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66038, encodeId=23566603856, content=内分泌科常用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66039, encodeId=596c6603936, content=副作用挺大的, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66040, encodeId=85786604051, content=慎重用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66041, encodeId=828966041d2, content=双刃剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=)]
    2016-02-27 1de47ca2m12(暂无匿称)

    内分泌科常用

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1951427, encodeId=18f4195142e64, content=<a href='/topic/show?id=25305234439' target=_blank style='color:#2F92EE;'>#急性痛风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52344, encryptionId=25305234439, topicName=急性痛风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Nov 03 04:43:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772688, encodeId=e6931e7268874, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Thu Sep 08 12:43:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66124, encodeId=856966124e3, content=看看吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66125, encodeId=4f9b661257b, content=先学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553884, encodeId=5ad8155388416, content=<a href='/topic/show?id=adbe650e465' target=_blank style='color:#2F92EE;'>#泼尼松龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65074, encryptionId=adbe650e465, topicName=泼尼松龙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4914457810, createdName=xjy07, createdTime=Sun Feb 28 09:43:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66063, encodeId=be62660638f, content=不太懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat Feb 27 23:11:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66038, encodeId=23566603856, content=内分泌科常用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66039, encodeId=596c6603936, content=副作用挺大的, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66040, encodeId=85786604051, content=慎重用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66041, encodeId=828966041d2, content=双刃剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=)]
    2016-02-27 1de47ca2m12(暂无匿称)

    副作用挺大的

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1951427, encodeId=18f4195142e64, content=<a href='/topic/show?id=25305234439' target=_blank style='color:#2F92EE;'>#急性痛风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52344, encryptionId=25305234439, topicName=急性痛风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Nov 03 04:43:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772688, encodeId=e6931e7268874, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Thu Sep 08 12:43:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66124, encodeId=856966124e3, content=看看吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66125, encodeId=4f9b661257b, content=先学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553884, encodeId=5ad8155388416, content=<a href='/topic/show?id=adbe650e465' target=_blank style='color:#2F92EE;'>#泼尼松龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65074, encryptionId=adbe650e465, topicName=泼尼松龙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4914457810, createdName=xjy07, createdTime=Sun Feb 28 09:43:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66063, encodeId=be62660638f, content=不太懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat Feb 27 23:11:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66038, encodeId=23566603856, content=内分泌科常用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66039, encodeId=596c6603936, content=副作用挺大的, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66040, encodeId=85786604051, content=慎重用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66041, encodeId=828966041d2, content=双刃剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=)]
    2016-02-27 1de47ca2m12(暂无匿称)

    慎重用药

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1951427, encodeId=18f4195142e64, content=<a href='/topic/show?id=25305234439' target=_blank style='color:#2F92EE;'>#急性痛风#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52344, encryptionId=25305234439, topicName=急性痛风)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ce68183, createdName=xiongke010, createdTime=Thu Nov 03 04:43:00 CST 2016, time=2016-11-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1772688, encodeId=e6931e7268874, content=<a href='/topic/show?id=871064e139b' target=_blank style='color:#2F92EE;'>#治疗选择#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64713, encryptionId=871064e139b, topicName=治疗选择)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=015a38388258, createdName=liye789132264, createdTime=Thu Sep 08 12:43:00 CST 2016, time=2016-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66124, encodeId=856966124e3, content=看看吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=129, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66125, encodeId=4f9b661257b, content=先学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=151, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=45101626056, createdName=忠诚向上, createdTime=Sun Feb 28 11:50:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1553884, encodeId=5ad8155388416, content=<a href='/topic/show?id=adbe650e465' target=_blank style='color:#2F92EE;'>#泼尼松龙#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65074, encryptionId=adbe650e465, topicName=泼尼松龙)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fb4914457810, createdName=xjy07, createdTime=Sun Feb 28 09:43:00 CST 2016, time=2016-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66063, encodeId=be62660638f, content=不太懂, beContent=null, objectType=article, channel=null, level=null, likeNumber=118, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat Feb 27 23:11:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66038, encodeId=23566603856, content=内分泌科常用, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66039, encodeId=596c6603936, content=副作用挺大的, beContent=null, objectType=article, channel=null, level=null, likeNumber=139, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66040, encodeId=85786604051, content=慎重用药, beContent=null, objectType=article, channel=null, level=null, likeNumber=7, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=66041, encodeId=828966041d2, content=双刃剑, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4a6b1686125, createdName=1de47ca2m12(暂无匿称), createdTime=Sat Feb 27 18:28:00 CST 2016, time=2016-02-27, status=1, ipAttribution=)]
    2016-02-27 1de47ca2m12(暂无匿称)

    双刃剑

    0

相关资讯

ESC 2014:免疫疗法对结核性心包炎患者无益

欧洲心脏病学会(ESC)2014年会公布的IMPI研究表明,泼尼松龙和分支杆菌indicus pranii(MIP)两种免疫疗法均未对结核性心包炎患者产生获益,反而与癌症发生率增加相关。该研究同时发表于《新英格兰医学杂志》(简称NEJM)。 此项2×2阶乘试验从8个国家的19家医院共纳入1400例伴有心包积液的确诊或临床诊断结核性心包炎成人患者。患者首先随机接受安慰剂或泼尼松龙治

Ann Intern Med:泼尼松龙——急性痛风的一线治疗药物

Ann Intern Med:泼尼松龙——急性痛风的一线治疗药物最近的两项双盲随机对照试验(RCTs)表明,痛风治疗时口服类固醇和非甾体类抗炎药的镇痛效果相似,但是这两项试验的样本量较小,同时还存在一些方法学上的局限性。本研究旨在对比急诊科(EDs)急性痛风患者口服泼尼松龙与口服吲哚美辛治疗的安全性和有效性。设计一项多中心,双盲,随机等效性试验。共纳入了416名18岁及以上的患者(来自香港的4家E

Baidu
map
Baidu
map
Baidu
map